BIM
DRNA

Bogle Investment Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bogle Investment Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,798
Closed -$180K – 379
2018
Q1 		$180K Buy
+18,798
New +$203K 0.01% 295

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bogle Investment Management's DRNA Position: Q2 2018 in Review

Bogle Investment Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2018, closing a stake of 18,798 shares — an estimated $180K sold.

Bogle Investment Management first reported a position in DRNA in Q1 2018 and held it in 1 quarter. The position peaked at $180K in Q1 2018. 85 funds tracked by Wall St. Rank hold DRNA as of Q2 2018.

  • Bogle Investment Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Bogle Investment Management sold 18,798 Dicerna Pharmaceuticals, Inc. shares in Q2 2018, an estimated $180K.
  • Bogle Investment Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Bogle Investment Management's Dicerna Pharmaceuticals, Inc. position peaked at $180K in Q1 2018.
  • 85 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2018.

Based on Bogle Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.